{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:18:29Z","timestamp":1793333909206,"version":"4.5.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Diabetic Kidney Disease (DKD) is a primary cause of end-stage renal disease, characterized by podocyte dysfunction. While current clinical biomarkers including albuminuria and estimated glomerular filtration rate are foundational for diagnosis, they often function as lagging indicators and fail to detect early renal injury. Recently, N6-methyladenosine (m6A) RNA methylation has emerged as a key epitranscriptomic link between hyperglycemia and podocyte injury, offering a novel frontier for diagnostic biomarker discovery. This review shifts the traditional focus from basic molecular mechanisms to the preclinical translational potential of m6A regulators and their downstream targets as early detection tools. Current experimental evidence in cell and animal models indicates that the abnormal upregulation of\n                    <jats:italic>METTL3<\/jats:italic>\n                    ,\n                    <jats:italic>METTL14<\/jats:italic>\n                    , and\n                    <jats:italic>FTO<\/jats:italic>\n                    may reshape podocyte fate through complex regulatory pathways. These alterations appear to enhance the stability of harmful transcripts while degrading protective ones. Furthermore, specific regulators and their associated hub genes, such as\n                    <jats:italic>CTSS<\/jats:italic>\n                    and\n                    <jats:italic>CD53<\/jats:italic>\n                    , show emerging promise as candidate non-invasive biomarkers that correlate with immune infiltration and early renal function decline in preclinical settings, though robust clinical validation remains necessary.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1886521","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:10:25Z","timestamp":1784718625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The translational potential of m6A RNA methylation in DKD: emerging biomarkers for early detection and targeted therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Huihui","family":"Liu","sequence":"first","affiliation":[{"name":"Second Affiliated Hospital, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[{"name":"Heilongjiang Academy of Chinese Medicine Sciences","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Dai","sequence":"additional","affiliation":[{"name":"Heilongjiang Academy of Chinese Medicine Sciences","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Wu","sequence":"additional","affiliation":[{"name":"Heilongjiang Academy of Chinese Medicine Sciences","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"An","sequence":"additional","affiliation":[{"name":"Heilongjiang Academy of Chinese Medicine Sciences","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1624077","DOI":"10.3389\/fphys.2025.1624077","article-title":"The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease.","volume":"16","author":"Deng","year":"2025","journal-title":"Front Physiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/IMNA-D-23-00029","article-title":"Update on the pathogenesis, diagnosis, and treatment of diabetic tubulopathy.","volume":"11","author":"Liu","year":"2024","journal-title":"Integrat Med Nephrol Androl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1097\/IMNA-D-24-00036","article-title":"Selective autophagy in kidney diseases: the tip of the iceberg.","volume":"12","author":"Gong","year":"2025","journal-title":"Integr Med Nephrol Androl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease.","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4093\/dmj.2021.0329","article-title":"Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease.","volume":"46","author":"Jung","year":"2022","journal-title":"Diabetes Metab J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association.","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2786470","DOI":"10.1155\/2018\/2786470","article-title":"Association of EPHX2 R287Q polymorphism with diabetic nephropathy in Chinese type 2 diabetic patients.","volume":"2018","author":"Ma","year":"2018","journal-title":"J Diabetes Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1802447","DOI":"10.3389\/fendo.2026.1802447","article-title":"Integration of digital physicalomics and dual-fluid metabolomics flux ratios reveals tubular secretory dysfunction in early diabetic kidney disease.","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B9","doi-asserted-by":"publisher","first-page":"112560","DOI":"10.1016\/j.intimp.2024.112560","article-title":"Morroniside attenuates podocytes lipid deposition in DKD: a network pharmacology, molecular docking and experimental validation study.","volume":"138","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1296843","DOI":"10.3389\/fendo.2024.1296843","article-title":"Research progress on the treatment of diabetic nephropathy with leech and its active ingredients.","volume":"15","author":"Tian","year":"2024","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12964-024-01502-3","article-title":"Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review.","volume":"22","author":"Hu","year":"2024","journal-title":"Cell Commun Signal."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00026","DOI":"10.1097\/IMNA-D-22-00026","article-title":"New insights into traditional Chinese medicine in treatment of DKD.","volume":"10","author":"Chung","year":"2023","journal-title":"Integrat Med Nephrol Androl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1505637","DOI":"10.3389\/fphar.2025.1505637","article-title":"Regulation of autophagy by the PI3K-AKT pathway in Astragalus membranaceus-Cornus officinalis to ameliorate DKD.","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1669557","DOI":"10.3389\/fnut.2025.1669557","article-title":"Natural compounds regulating fatty acid oxidation in the treatment of diabetic kidney disease.","volume":"12","author":"Sun","year":"2025","journal-title":"Front Nutr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.7150\/ijbs.81892","article-title":"Emerging role of ferroptosis in diabetic kidney disease: molecular mechanisms and therapeutic opportunities.","volume":"19","author":"Wang","year":"2023","journal-title":"Int J Biol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-00872-8","article-title":"m(6)A-binding proteins: the emerging crucial performers in epigenetics.","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12967-025-06221-y","article-title":"m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","article-title":"The potential role of RNA N6-methyladenosine in Cancer progression.","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"126773","DOI":"10.1016\/j.ijbiomac.2023.126773","article-title":"The functions and mechanisms of post-translational modification in protein regulators of RNA methylation: current status and future perspectives.","volume":"253","author":"Chen","year":"2023","journal-title":"Int J Biol Macromol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12967-025-06817-4","article-title":"Decoding m(6)A RNA methylation in kidney disorders: from molecular insights to therapeutic strategies.","volume":"23","author":"Yao","year":"2025","journal-title":"J Transl Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-024-02041-8","article-title":"The role of RNA methylation in tumor immunity and its potential in immunotherapy.","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.ymthe.2022.01.002","article-title":"METTL3-mediated m(6)A modification of TIMP2 mRNA promotes podocyte injury in DKD.","volume":"30","author":"Jiang","year":"2022","journal-title":"Mol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70627","DOI":"10.1111\/jcmm.70627","article-title":"The impact of METTL3 on MDM2 promotes podocytes injury during diabetic kidney disease.","volume":"29","author":"Wu","year":"2025","journal-title":"J Cell Mol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2497492","DOI":"10.1080\/0886022X.2025.2497492","article-title":"METTL3 promotes podocyte pyroptosis in DKD through N(6)-methyladenosine modification of TRIM29 mRNA.","volume":"47","author":"Xu","year":"2025","journal-title":"Ren Fail."},{"key":"B25","doi-asserted-by":"publisher","first-page":"115677","DOI":"10.1016\/j.ejmech.2023.115677","article-title":"METTL3-mediated N6-methyladenosine modification stimulates mitochondrial damage and ferroptosis of kidney tubular epithelial cells following acute kidney injury by modulating the stabilization of MDM2-p53-LMNB1 axis.","volume":"259","author":"Hu","year":"2023","journal-title":"Eur J Med Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/ijms24021403","article-title":"METTL3 regulates osteoclast biological behaviors via iNOS\/NO-mediated mitochondrial dysfunction in inflammatory conditions.","volume":"24","author":"Li","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jdi.14113","article-title":"METTL3\/YTHDF2 m6A axis mediates the progression of DKD through epigenetically suppressing PINK1 and mitophagy.","volume":"15","author":"Wang","year":"2024","journal-title":"J Diabetes Investig."},{"key":"B28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.tcb.2016.05.008","article-title":"Deciphering the molecular signals of PINK1\/parkin mitophagy.","volume":"26","author":"Nguyen","year":"2016","journal-title":"Trends Cell Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00592-023-02145-5","article-title":"METTL14 promotes the development of diabetic kidney disease by regulating m(6)A modification of TUG1.","volume":"60","author":"Zheng","year":"2023","journal-title":"Acta Diabetol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"150524","DOI":"10.1016\/j.bbrc.2024.150524","article-title":"WTAP and METTL14 regulate the m6A modification of DKK3 in renal tubular epithelial cells of DKD.","volume":"738","author":"Fu","year":"2024","journal-title":"Biochem Biophys Res Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41419-021-04156-y","article-title":"METTL14 aggravates podocyte injury and glomerulopathy progression through N(6)-methyladenosine-dependent downregulating of Sirt1.","volume":"12","author":"Lu","year":"2021","journal-title":"Cell Death Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.kint.2017.12.008","article-title":"Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.","volume":"93","author":"Hong","year":"2018","journal-title":"Kidney Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"F621","DOI":"10.1152\/ajprenal.00255.2017","article-title":"Reduction in podocyte SIRT1 accelerates kidney injury in aging mice.","volume":"313","author":"Chuang","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"888611","DOI":"10.3389\/fendo.2022.888611","article-title":"TangShenWeiNing formula prevents DKD by protecting podocytes through the SIRT1\/HIF-1\u03b1 pathway.","volume":"13","author":"Chang","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s10020-023-00764-w","article-title":"The role of N-methyladenosine modification in acute and chronic kidney diseases.","volume":"29","author":"Qi","year":"2023","journal-title":"Mol Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"10.1681\/ASN.2025nsy80m24","DOI":"10.1681\/ASN.2025nsy80m24","article-title":"FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease: SA-PO0310.","volume":"36","author":"Lv","year":"2025","journal-title":"J Am Soc Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e70332","DOI":"10.1096\/fj.202403014R","article-title":"m6A demethylase Fto inhibited macrophage activation and glycolysis in DKD via m6A\/Npas2\/Hif-1\u03b1 axis.","volume":"39","author":"Zhu","year":"2025","journal-title":"FASEB J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"116819","DOI":"10.1016\/j.bcp.2025.116819","article-title":"FTO aggravates podocyte injury and DKD progression via m6A-dependent stabilization of ACC1 mRNA and promoting fatty acid metabolism.","volume":"235","author":"Chang","year":"2025","journal-title":"Biochem Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1159\/000547688","article-title":"m(6)A eraser FTO promotes ATF3 expression impairing podocyte autophagy in DKD.","volume":"11","author":"Zhang","year":"2025","journal-title":"Kidney Dis (Basel)."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3560238","DOI":"10.1155\/2017\/3560238","article-title":"Podocyte autophagy: a potential therapeutic target to prevent the progression of DKD.","volume":"2017","author":"Liu","year":"2017","journal-title":"J Diab Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1090989","DOI":"10.3389\/fimmu.2022.1090989","article-title":"Epigenetics and endoplasmic reticulum in podocytopathy during DKD progression.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.62347\/FTQC1190","article-title":"Astragaloside IV in type 2 diabetic vascular complications: from traditional mechanisms to an emerging epitranscriptomic (m6A) perspective.","volume":"18","author":"Kang","year":"2026","journal-title":"Am J Transl Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"112303","DOI":"10.1016\/j.intimp.2024.112303","article-title":"Hederagenin improves renal fibrosis in DKD by regulating Smad3\/NOX4\/SLC7A11 signaling-mediated tubular cell ferroptosis.","volume":"135","author":"Jia","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/jdi.70094","article-title":"METTL3\/YTHDF3 m(6)A axis promotes ferroptosis in diabetic kidney disease by stabilizing TfR1.","volume":"16","author":"Zhang","year":"2025","journal-title":"J Diab Investig."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e70714","DOI":"10.1096\/fj.202403207R","article-title":"Mitigation of ferroptosis in diabetic kidney disease through mesenchymal stem cell intervention via the Smad2\/3\/METTL3\/S1PR1 Axis.","volume":"39","author":"Huang","year":"2025","journal-title":"FASEB J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.7150\/ijbs.96233","article-title":"m6A RNA methylation drives kidney fibrosis by upregulating \u03b2-catenin signaling.","volume":"20","author":"Long","year":"2024","journal-title":"Int J Biol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1515\/jtim-2025-0093","article-title":"Co-targeting ferroptosis and immune evasion through small molecules in breast cancer.","volume":"13","author":"Zhou","year":"2025","journal-title":"J Transl Int Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1247690","DOI":"10.3389\/fmed.2023.1247690","article-title":"The role of N6-methyladenosine (m(6)A) in kidney diseases.","volume":"10","author":"You","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1494162","DOI":"10.3389\/fmed.2025.1494162","article-title":"Diabetic kidney disease: m6A modification as a marker of disease progression and subtype classification.","volume":"12","author":"Li","year":"2025","journal-title":"Front Med (Lausanne)."},{"key":"B50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12882-025-04314-w","article-title":"CTSS and CD53: emerging m6A methylation markers in diabetic kidney disease pathogenesis and their clinical implications.","volume":"26","author":"Leilei","year":"2025","journal-title":"BMC Nephrol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/jcm4051010","article-title":"Biomarkers of renal disease and progression in patients with diabetes.","volume":"4","author":"Hojs","year":"2015","journal-title":"J Clin Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1506896","DOI":"10.3389\/fphar.2025.1506896","article-title":"Landscape analysis of m6A modification regulators reveals LRPPRC as a key modulator in tubule cells for DKD: a multi-omics study.","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4149\/gpb_2025020","article-title":"WTAP regulates DDX3Y mRNA via m6A modification to promote high glucose-induced podocytes injury and DKD progression.","volume":"44","author":"Li","year":"2025","journal-title":"Gen Physiol Biophys."},{"key":"B54","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1089\/ars.2024.0631","article-title":"M6A RNA methylation-mediated TUG1 stability maintains mitochondrial homeostasis during kidney aging by epigenetically regulating PGC1-\u03b1 expression.","volume":"41","author":"Zhu","year":"2024","journal-title":"Antioxid Redox Signal."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2521455","DOI":"10.1080\/0886022X.2025.2521455","article-title":"METTL3 alleviates renal tubular mitochondrial dysfunction by regulating the TUG1\/PGC-1a axis in an IGF2BP2-dependent manner in DKD.","volume":"47","author":"Chen","year":"2025","journal-title":"Renal Failure."},{"key":"B56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/dom.70220","article-title":"Renal lipotoxicity in diabetic and obesity-associated kidney diseases: molecular mechanisms and therapeutic targeting.","volume":"28","author":"Liu","year":"2026","journal-title":"Diabetes Obes Metab."},{"key":"B57","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s11033-025-11040-x","article-title":"METTL3-mediated m(6)A methylation: implications for diabetes pathogenesis and therapeutic potential.","volume":"52","author":"Wang","year":"2025","journal-title":"Mol Biol Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1552704","DOI":"10.3389\/fimmu.2025.1552704","article-title":"Roles of METTL3 and NLRP3 in pyroptosis and prospects in SCIRI.","volume":"16","author":"Guan","year":"2025","journal-title":"Front Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"116867","DOI":"10.1016\/j.bcp.2025.116867","article-title":"Inhibition of METTL3 promotes mesangial cell mitophagy and attenuates glomerular damage by alleviating FOSL1 m6A modifications via IGF2BP2-dependent mechanisms.","volume":"236","author":"Liu","year":"2025","journal-title":"Biochem Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41419-025-08019-8","article-title":"Hepatic steatosis and pyroptosis are induced by the hepatitis B virus X protein via B56\u03b1-METTL3 interaction-mediated m6A modification of the NLRP3 mRNA.","volume":"16","author":"Du","year":"2025","journal-title":"Cell Death Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ymthe.2024.01.037","article-title":"m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis.","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.7150\/thno.54967","article-title":"The crosstalk between m6A RNA methylation and other epigenetic regulators: a novel perspective in epigenetic remodeling.","volume":"11","author":"Zhao","year":"2021","journal-title":"Theranostics."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1002\/ctm2.942","article-title":"FTO-mediated m6A modification of SOCS1 mRNA promotes the progression of diabetic kidney disease.","volume":"12","author":"Sun","year":"2022","journal-title":"Clin Transl Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.tips.2023.09.013","article-title":"m6A epitranscriptomic modification in diabetic microvascular complications.","volume":"44","author":"Lin","year":"2023","journal-title":"Trends Pharmacol Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2400308","DOI":"10.1002\/smsc.202400308","article-title":"m6A ribonucleic acid methylation in fibrotic diseases of visceral organs.","volume":"5","author":"Dai","year":"2025","journal-title":"Small Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12033-023-00991-w","article-title":"Identification of key genes mediated by N6-methyladenosine methyltransferase METTL3 in ischemic stroke via bioinformatics analysis and experiments.","volume":"67","author":"Liang","year":"2025","journal-title":"Mol Biotechnol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.molmed.2024.11.001","article-title":"m(6)A and beyond: RNA modifications shaping angiogenesis.","volume":"31","author":"Luan","year":"2025","journal-title":"Trends Mol Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/a-2625-6822","article-title":"METTL14 promotes HK-2 cell injury in DKD through the regulation of THBS2 expression in an m6A-YTHDF2-dependent manner.","volume":"133","author":"Zhang","year":"2025","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e105977","DOI":"10.15252\/embj.2020105977","article-title":"m(6) A RNA methylation: from mechanisms to therapeutic potential.","volume":"40","author":"He","year":"2021","journal-title":"Embo J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1042\/BST20230574","article-title":"RNA m6A modification, signals for degradation or stabilisation?","volume":"52","author":"Wei","year":"2024","journal-title":"Biochem Soc Trans."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/IMNA-D-24-00018","article-title":"New insights into the use of traditional chinese medicine for treating diabetic kidney disease by regulating DNA methylation.","volume":"11","author":"Li","year":"2024","journal-title":"Integr. Med. Nephrol. Androl."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1886521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:10:26Z","timestamp":1784718626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1886521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":71,"alternative-id":["10.3389\/fmed.2026.1886521"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1886521","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1886521"}}